Could a daily injection spare babies with dwarfism from risky neck surgery?
NCT ID NCT04554940
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called vosoritide in infants with achondroplasia (the most common form of dwarfism) who are at high risk of needing a surgery to relieve pressure on the spinal cord at the base of the skull. The main goal is to see if the drug is safe and if it can help enlarge the skull opening, potentially reducing the need for surgery. About 20 babies under 12 months old will receive the drug or standard care, and their health will be closely monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital
London, SE1 7EH, United Kingdom
-
Murdoch Children's Research Institute
Parkville, Victoria, 3052, Australia
-
Sheffield Children's NHS Foundation Trust
Sheffield, S10 2TH, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a weekly shot help children with achondroplasia grow taller?
- Can growth hormone boost height in children with dwarfism?
- Weekly shot may boost growth in kids with dwarfism
- Experimental achondroplasia drug trial halted early
- No treatment, just tracking: PROPEL study watches how kids with achondroplasia grow
- New drug aims to boost height in kids with dwarfism